{"id":"NCT01625897","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","officialTitle":"A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-05","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-06-22","resultsPosted":"2021-04-13","lastUpdate":"2021-04-13"},"enrollment":125,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"MP-214","otherNames":[]},{"type":"DRUG","name":"Risperidone","otherNames":[]}],"arms":[{"label":"MP-214 1.5-9mg","type":"EXPERIMENTAL"},{"label":"Risperidone 2-12mg","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"Up to 60 weeks","effectByArm":[{"arm":"MP-214 1.5-9mg","deltaMin":78,"sd":null},{"arm":"Risperidone 2-12mg","deltaMin":42,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":83},"commonTop":["Nasopharyngitis","Schizophrenia","Insomnia","Hyperprolactinaemia","Blood prolactin increased"]}}